Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The European Society of Cardiology and European Renal Association have released their first-ever joint cardiorenal guidelines, pushing for routine kidney screening in all cardiac patients and standardized multi-drug protective regimens. The guidelines introduce the "STAMP" framework and recommend combining RAS inhibitors, SGLT2 inhibitors, and statins as foundational therapy. It's a major step toward treating the heart and kidneys as the interconnected system they truly are.
The European Society of Cardiology (ESC) and European Renal Association (ERA) have jointly released their first-ever cardiorenal guidelines, marking a significant shift toward integrated management of cardiovascular disease (CVD) and chronic kidney disease (CKD). The guidelines call for mandatory dual-parameter CKD screening in all cardiac patients — using both eGFR and urine albumin-to-creatinine ratio — and introduce the structured "STAMP" clinical framework: Screen, Triage, Address CKD factors, Modify CVD care, and Plan multidisciplinary follow-up.
Clinicians are urged to overcome "eGFR anxiety" — the tendency to withhold protective therapies or delay procedures like coronary angiography due to fear of kidney metric fluctuations. Task force co-chair Dr. Kevin Damman emphasized that mild early eGFR dips are expected and are ultimately outweighed by long-term cardiorenal benefits.
Key Takeaways:
Why it matters: Cardiovascular and kidney disease affect and amplify each other, yet have historically been managed in silos. These guidelines give clinicians a unified, actionable roadmap to protect both organs simultaneously — potentially reducing major adverse events for millions of patients worldwide.
